Treatment of Hemorrhagic Cystitis
Initial Management and Resuscitation
- The American College of Radiology recommends immediate hydration with forced diuresis to dilute toxic metabolites and reduce bladder toxicity, with a goal of 2-3 L in 24 hours 2
- Continuous bladder irrigation with normal saline and clot evacuation should be initiated for active bleeding, as recommended by the European Association of Urology 1
- Checking vital signs, hemoglobin, hematocrit, and coagulation parameters is essential to assess bleeding severity, according to the American College of Radiology 2
- Performing urine analysis and culture to exclude infection as a contributing cause is crucial, as suggested by the European Association of Urology and the American College of Radiology 1, 2
Stepwise Treatment Algorithm
First-Line Medical Management
- The European Association of Urology recommends non-steroidal anti-inflammatory drugs (NSAIDs) for pain control, with a strength of evidence rated as moderate 1, 2
- Anticholinergic agents such as oxybutynin are recommended for urinary frequency, urgency, and bladder spasm symptoms, with a high level of evidence supporting their use 1, 2
- Analgesics such as phenazopyridine are suggested for dysuria, with a low to moderate level of evidence 1
Second-Line Interventions
- Endoscopic fulguration is recommended for bleeding control when conservative measures fail, with a high level of evidence supporting its use 1
- Botulinum toxin A injection into the detrusor muscle is suggested when drug therapy proves ineffective, with a moderate level of evidence 1, 2
Prevention Strategies
- The American Society of Clinical Oncology recommends mesna administration to bind the toxic metabolite acrolein in patients receiving cyclophosphamide or ifosfamide chemotherapy, with a high level of evidence supporting its use 2
- For ifosfamide specifically, mesna should be given as IV bolus at 20% of the ifosfamide dose at time of administration, followed by oral mesna at 40% of the ifosfamide dose at 2 and 6 hours after each dose, as recommended by the American Society of Clinical Oncology 2
- Patients who vomit within 2 hours of oral mesna must repeat the dose or receive IV mesna, with a moderate level of evidence supporting this recommendation 2
- Monthly monitoring of urine for red blood cells is recommended for patients on cyclophosphamide, with a low to moderate level of evidence 2
Monitoring Requirements
- The European Association of Urology recommends monitoring urine output and appearance continuously for signs of ongoing or worsening hematuria, with a high level of evidence supporting this recommendation 2
- Assessing renal function regularly, particularly in patients with pre-existing renal impairment, is crucial, with a moderate level of evidence supporting this recommendation 2
- Watching for signs of urinary tract infection is essential, as hemorrhagic cystitis predisposes to secondary infections, with a low to moderate level of evidence 2
- For radiation cystitis, bladder bleeding may peak around 30 months post-treatment, after which prevalence rates typically return to baseline, with a moderate level of evidence supporting this finding 1